DB289 Approval Status
FDA Approved: No
Brand name: DB289
Generic name: pafuramidine
Company: Immtech Pharmaceuticals, Inc.
Treatment for: Pneumocystis Pneumonia
DB289 (pafuramidine) is an investigational drug intended for use in the treatment of pneumocystis pneumonia.
In November 2006, Immtech Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted orphan drug designation for pafuramidine (DB289) to treat Pneumocystis jiroveci pneumonia (PCP), a common life-threatening opportunistic infection in HIV/AIDS and other immunosuppressed patients.
Development Status and FDA Approval Process for DB289
|Nov 21, 2006||US FDA Grants Immtech's Oral Drug Candidate Pafuramidine (DB289) Orphan Drug Status for Treatment of PCP|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.